Literature DB >> 17344023

Unilateral, clinically T2N0, squamous cell carcinoma of the tongue: surgical outcome analysis.

Y C Lim1, E C Choi.   

Abstract

To determine the survival rate and analyse the predicting factors of recurrence in patients with unilateral, clinically T2N0 squamous cell carcinoma (SCC) of the tongue which does not cross the midline, a retrospective analysis of 32 such consecutive, previously untreated, cases was performed. All patients were initially treated by surgery between January 1992 and May 2004. All patients had neck dissections: 12 continuous, 20 discontinuous, 24 bilateral and 8 unilateral. Fourteen patients (44%) received adjunctive postoperative radiotherapy. Occult metastatic rates were 34% and 4% in ipsilateral and contralateral neck, respectively. Patients with pN0 cancer had a better 5-year disease-specific survival rate than those with pN+ cancer (85% versus 41%, P=0.005). Twelve patients (38%) had recurrences after the initial treatment. The recurrence rate was significantly higher in patients with pathologic nodal metastasis, peroral resection of the primary tumour or discontinuous neck dissection. The results suggest that the most effective surgical methods for treating unilateral T2N0 SCC of the tongue which does not cross the midline are: pull-through approach for primary lesion instead of peroral approach; continuous rather than discontinuous neck dissection and ipsilateral elective rather than bilateral routine elective neck dissection.

Entities:  

Mesh:

Year:  2007        PMID: 17344023     DOI: 10.1016/j.ijom.2007.01.009

Source DB:  PubMed          Journal:  Int J Oral Maxillofac Surg        ISSN: 0901-5027            Impact factor:   2.789


  7 in total

1.  Operable Oral Tongue Squamous Cell Cancer: 15 Years Experience at a Tertiary Care Center in North India.

Authors:  Nootan Kumar Shukla; S V Suryanarayana Deo; Pankaj Kumar Garg; N M L Manjunath; Suman Bhaskar; V Sreenivas
Journal:  Indian J Surg Oncol       Date:  2017-05-11

2.  Patients with unilateral squamous cell carcinoma of the tongue and ipsilateral lymph node metastasis do not profit from bilateral neck dissection.

Authors:  Christoph Klingelhöffer; Andreas Gründlinger; Gerrit Spanier; Stephan Schreml; Maximilian Gottsauner; Steffen Mueller; Johannes K Meier; Torsten E Reichert; Tobias Ettl
Journal:  Oral Maxillofac Surg       Date:  2018-03-29

3.  Clinical outcome of surgical treatment of T1-2 N0 squamous cell carcinoma of oral tongue with observation for the neck: Analysis of 176 cases.

Authors:  Arsheed Hussain Hakeem; Sultan Ahmed Pradhan; Rajan Kannan; Jagadish Tubachi
Journal:  Ann Maxillofac Surg       Date:  2016 Jul-Dec

4.  Elective Neck Dissection Versus Observation in Early-Stage (cT1/T2N0) Oral Squamous Cell Carcinoma.

Authors:  Jin-Yong Liu; Chieh-Feng Chen; Chyi-Huey Bai
Journal:  Laryngoscope Investig Otolaryngol       Date:  2019-08-14

5.  Application of "parachute" technique for free flap reconstruction in advanced tongue cancer after ablation without lip-jaw splitting: A retrospective case study.

Authors:  Chin-Jui Liu; Ku-Hao Fang; Chang-Cheng Chang; Erh-Ti Lin; Geng-He Chang; Jen-Hsiang Shen; Yu-Tsung Chen; Yao-Te Tsai
Journal:  Medicine (Baltimore)       Date:  2019-08       Impact factor: 1.817

Review 6.  A systematic review and meta-analysis of the prognostic role of age in oral tongue cancer.

Authors:  Marta Tagliabue; Pietro Belloni; Rita De Berardinis; Sara Gandini; Francesco Chu; Stefano Zorzi; Caterina Fumagalli; Luigi Santoro; Susanna Chiocca; Mohssen Ansarin
Journal:  Cancer Med       Date:  2021-03-24       Impact factor: 4.452

7.  Treatment and Prognosis of Oral Cancer Patients with Confirmed Contralateral Neck Metastasis: A Multicenter Retrospective Analysis.

Authors:  Yuki Sakamoto; Mitsunobu Otsuru; Takumi Hasegawa; Masaya Akashi; Shin-Ichi Yamada; Hiroshi Kurita; Masaya Okura; Nobuhiro Yamakawa; Tadaaki Kirita; Souichi Yanamoto; Masahiro Umeda; Yuka Kojima
Journal:  Int J Environ Res Public Health       Date:  2022-07-28       Impact factor: 4.614

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.